Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 278, Issue 6 47-6, 2000, Pages

  Takahashi, Yasushi ^a   Roman, Christine ^a   Chemtob, Sylvain ^c   Tse, Mary M ^a   Lin, Emil ^a   Heymann, Michael A ^a,b   Clyman, Ronald I ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Celecoxib; Cyclooxygenase; Cyclooxygenase 1; Cyclooxygenase 2; Indomethacin; Prostaglandin E2; Prostaglandin I2

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; PROSTACYCLIN; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ARTERY BLOOD FLOW; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DUCTUS ARTERIOSUS; FETUS; HEMODYNAMICS; LAMB; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; TOCOLYSIS;

EID: 0033918684     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.2000.278.6.r1496     Document Type: Article

References (37)

1. Brash AR, Hickey DE, Graham TP, Oates JA, and Cotton RB. Pharmacokinetics of indomethacin in the neonate. N Engl J Med 305: 67-72, 1981.
2. Chan C-C, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, and Penneton M. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 274: 1531-1537, 1995.
3. Clyman RI, Hardy P, Waleh N, Chen YQ, Mauray F, Fouron J-C, and Chemtob S. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am J Physiol Regulatory Integrative Comp Physiol 276: R913-R921, 1999.
4. 1α. Prostaglandins 16: 259-264, 1978.
5. 2 concentrations and patent ductus arteriosus in fetal and neonatal lambs. J Pediatr 97: 455-461, 1980.
6. Clyman RI, Mauray F, Wong L, Heymann MA, and Rudolph AM. The developmental response of the ductus arteriosus to oxygen. Biol Neonate 34: 177-181, 1978.
7. Clyman RI, Saugstad OD, and Mauray F. Reactive oxygen metabolites relax the lamb ductus arteriosus by stimulating prostaglandin production. Circ Res 64: 1-8, 1989.
8. Coceani F and Olley PM. The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol 51: 220-225, 1973.
9. Eronen M. The hemodynamic effects of antenatal indomethacin and a beta-sympathomimetic agent on the fetus and the new-born: a randomized study. Pediatr Res 33: 615-619, 1993.
10. Eronen M, Pesonen E, Kurki T, Ylikorkala O, and Hallman M. The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized double-blind study. Am J Obstet Gynecol 164: 141-146, 1991.
11. Fineman JR, Takahashi Y, Roman C, and Clyman RI. Endothelin-receptor blockade does not alter closure of the ductus arteriosus. Am J Physiol Heart Circ Physiol 275: H1620-H1626, 1998.
12. Fox JJ, Ziegler JW, Dunbar DI, Halbower AC, Kinsella JP, and Abman SH. Role of nitric oxide and cGMP system in regulation of ductus arteriosus tone in ovine fetus. Am J Physiol Heart Circ Physiol 271: H2638-H2645, 1996.
13. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, and Otomo S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24: 105-110, 1993.
14. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, and Ackerman NR. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254: 180-187, 1990.
15. Hanna N, Peri KG, Abran D, Hardy P, Doke A, Lachapelle P, Roy MS, Orquin J, Varma DR, and Chemtob S. Light induces peroxidation in retina by activating prostaglandin G/H synthase. Free Radic Biol Med 23: 885-897, 1997.
16. Heymann MA and Rudolph AM. Control of the ductus arteriosus. Physiol Rev 55: 62-78, 1975.
17. Hirst JJ, Teixeira FJ, Zakar T, and Olson DM. Prostaglandin endoperoxide-H synthase-1 and -2 messenger ribonucleic acid levels in human amnion with spontaneous labor onset. J Clin Endocrinol Metab 80: 517-523, 1995.
18. Johnson JL, Wimsatt J, Buckel SD, Dyer RD, and Maddipati KR. Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Arch Biochem Biophys 324: 26-34, 1995.
19. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, and Lee CA. Disruption of the mouse cyclooxygenase 1 gene. Characteristics of the mutant and areas of future study. Adv Exp Med Biol 407: 87-92, 1997.
20. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, and Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 267: 25934-25938, 1992.
21. Maier JA, Hla T, and Maciag T. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 265: 10805-10808, 1990.
22. Meade EA, Smith WL, and DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268: 6610-6614, 1993.
23. Meyers RL, Alpan G, Lin E, and Clyman RI. Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res 29: 569-574, 1991.
24. Moise KJ Jr, Huhta JC, Sharif DS, Ou CN, Kirshon B, Wasserstrum N, and Cano L. Indomethacin in the treatment of preterm labor: effects on the fetal ductus. N Engl J Med 319: 327-331, 1988.
25. Moise KJ, C Ou-N, Kirshon B, Cano LE, Rognerud C, and Carpenter RJ. Placental transfer of indomethacin in the human pregnancy. Obstet Gynecol 162: 549-554, 1990.
26. Momma K, Hagiwara H, and Konishi T. Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs: study of additional 34 drugs. Prostaglandins 28: 527-536, 1984.
27. Morham SG, Langenbach R, Mahler J, Smithies O. Characterization of prostaglandin H synthase 2 deficient mice and implications for mechanisms of NSAID action. Adv Exp Med Biol 407: 131-138, 1997.
28. O'Neill GP and Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330: 156-160, 1993.
29. Pace-Asciak CR and Rangaraj G. Prostaglandin biosynthesis and catabolism in the lamb ductus arteriosus, aorta and pulmonary artery. Biochim Biophys Acta 529: 13-20, 1978.
30. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, and Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesul-fonamide (SC-58635, celecoxib). J Med Chem 40: 1347-1365, 1997.
31. Peri KG, Hardy P, Li DY, Varma DR, and Chemtob S. Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. J Biol Chem 270: 24615-24620, 1995.
32. Sawdy R, Slater D, Fisk N, Edmonds DK, and Bennett P. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 350: 265-266, 1997.
33. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, and Geis GS. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41: 1591-1602, 1998.
34. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, and Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95: 13313-13318, 1998.
35. Van den Veyver IB, Moise KJ Jr, Ou CN, and Carpenter RJ Jr. The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. J Obstet Gynecol 82: 500-503, 1993.
36. Vane J. Towards a better aspirin. Nature 367: 215-216, 1994.
37. Vermillion ST, Scardo JA, Lashus AG, and Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 177: 256-261, 1997.